Salivary Cytokines as Potential Diagnostic Biomarkers for Systemic Lupus Erythematosus Disease

Zian, Zeineb; Bouhoudan, Assia; Mourabit, Nadira; Azizi, Gholamreza; Mechita, Mohcine Bennani

doi:10.1155/2021/8847557

Cited by 7 publications

(3 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To the best of our knowledge, this is the first study to investigate the role of S100A8 protein as a diagnostic biomarker and its association with disease activity in patients with SLE using serum, urine, and saliva. It is important to analyze the S100 protein in the saliva of patients with SLE, which is a biofluid that is gradually receiving special attention, as it has been acknowledged that it contains many informative proteins about the disease process (44). Although the diagnostic ability of S100A8 that we have demonstrated is not superior to the diagnostic sensitivity and specificity of previously proposed classification criteria (45), it is worth emphasizing that we have discovered a powerful diagnostic biomarker in various biofluids.…”

Section: Discussionmentioning

confidence: 75%

S100A8 in Serum, Urine, and Saliva as a Potential Biomarker for Systemic Lupus Erythematosus

et al. 2022

View full text Add to dashboard Cite

ObjectivesThis study aimed to elucidate the potential of serum, urine, and saliva S100 calcium-binding protein A8 protein (S100A8) levels as biomarkers for systemic lupus erythematosus (SLE).MethodsSerum, urine, and saliva samples were obtained from 249 patients with SLE from the Ajou lupus cohort and 52 age- and sex-matched healthy controls (HCs). The concentrations of S100A8 were quantified using an ELISA, and a receiver operating characteristic curve was used to analyze whether they may be used as biomarkers for diagnosing SLE.ResultsAmong 249 SLE patients included in our study, the mean SLE disease activity index (SLEDAI)-2K was 7.16 ± 5.61, and the number of patients with lupus flare was 11. Patients with SLE showed a 2.7-fold increase in serum S100A8 levels compared with that in HCs (1,890.6 vs. 709 pg/ml, p < 0.001). In urine and saliva, the average S100A8 levels were significantly higher in patients with SLE compared with those in HCs (urine, 2,029.4 vs. 1,096.7 pg/ml, p = 0.001; saliva, 290,496.3 vs. 47,742 pg/ml, p < 0.001). For SLE diagnosis, the area under the receiver operating characteristic curve was 0.831 for serum S100A8 (95% CI, 0.765–0.897), 0.751 for urine S100A8 (95% CI, 0.648–0.854), and 0.729 for salivary S100A8 (95% CI, 0.646–0.812). Pearson’s correlation analysis showed that S100A8 in serum, urine, and saliva was significantly associated with the SLEDAI (r = 0.267, p < 0.001; r = 0.274, p < 0.001; and r = 0.629, p < 0.001, respectively). Among the clinical manifestations, nephritis was the most influential factor related to SLE in the concentration of S100A8 in serum, urine, and saliva.ConclusionThis is the first study to show that the expression of S100A8 in serum, urine, and saliva is significantly higher in patients with SLE than in HCs and is associated with disease activity markers. Therefore, we suggest that S100A8 protein could be a potential biomarker for SLE.

show abstract

Section: Discussionmentioning

confidence: 75%

S100A8 in Serum, Urine, and Saliva as a Potential Biomarker for Systemic Lupus Erythematosus

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Some recent studies have focused on salivary inflammatory markers and they have found that salivary cytokines may be potential diagnostic biomarkers for SLE, where salivary IL-6 can be used to reliably assess the inflammatory process of SLE ( Stanescu et al, 2018 ; Zian et al, 2021 ).…”

Section: Manuscript Formattingmentioning

confidence: 99%

Pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus: A review

Liu

Zhang

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease with a complex pathogenesis. Neuropsychiatric systemic lupus erythematosus (NPSLE) is a serious complication of SLE that involves the nervous system and produces neurological or psychiatric symptoms. After decades of research, it is now believed that the diverse clinical manifestations of NPSLE are associated with intricate mechanisms, and that genetic factors, blood-brain barrier dysfunction, vascular lesions, multiple autoimmune antibodies, cytokines, and neuronal cell death may all contribute to the development of NPSLE. The complexity and diversity of NPSLE manifestations and the clinical overlap with other related neurological or psychiatric disorders make its accurate diagnosis difficult and time-consuming. Therefore, in this review, we describe the known pathogenesis and potential causative factors of NPSLE and briefly outline its treatment that may help in the diagnosis and treatment of NPSLE.

show abstract

“…Researchers are attempting to objectively assess the body's response to a range of conditions, not only systemic, such as systemic lupus erythematosus (SLE), tuberculosis, or malignant processes [14,15], but also oral conditions, including periodontitis [16], caries [17,18], lichen planus [19], or peri-implantitis [20]. To this end, the levels of various cytokines, such as IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IFN-γ, TNF-α, and CRP, are monitored for diagnostic and prognostic purposes, and their fluctuations are reflected in the patient's clinical condition or to assess the severity of the disease [21,22].…”

Section: Introductionmentioning

confidence: 99%

Advantages of Dynamic Navigation in Prosthetic Implant Treatment in Terms of the Clinical Evaluation and Salivary Pro-Inflammatory Biomarkers: A Clinical Study

Wachol,

Morawiec,

Szurko

et al. 2023

Applied Sciences

View full text Add to dashboard Cite

Successful implantation in augmented areas relies on adequate bone density and quality, along with thorough planning. The minimisation of the risks involved in the surgery and recovery phases is also of tremendous relevance. The aims of the present research were to clinically and biochemically evaluate the healing process after implant surgery (dental implants) using dynamic surgical navigation following prior bone augmentation. Thirty healthy patients who had implant treatment were analysed. The study participants (30 patients) were randomised between two groups. The 15 patients in the study group were treated with Navident dynamic navigation by using a flapless technique. The control group included 15 subjects in whom the implantation procedure was performed classically using the elevation flap full-thickness method. In all cases, the patient’s clinical condition, the patient’s subjective visual assessment of post-operative pain using the Visual Analogue Scale (VAS), and the levels of the salivary biomarkers interleukin 6 (IL 6) and C-reactive protein (CRP) immediately before surgery on the first post-operative day and on the seventh post-operative day were assessed. The healing process was shown to be faster in patients in the study group due to the low invasiveness of the treatment, which was confirmed by lower levels of pro-inflammatory cytokines in the study group versus the control group. The statistical analysis used Student’s t-test and Mann–Whitney test. The implementation of dynamic navigation and the application of the flapless technique reduced post-operative trauma, leading to a reduced risk of infection, reduced patient discomfort, and faster recovery.

show abstract

Salivary Cytokines as Potential Diagnostic Biomarkers for Systemic Lupus Erythematosus Disease

Cited by 7 publications

References 76 publications

S100A8 in Serum, Urine, and Saliva as a Potential Biomarker for Systemic Lupus Erythematosus

S100A8 in Serum, Urine, and Saliva as a Potential Biomarker for Systemic Lupus Erythematosus

Pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus: A review

Advantages of Dynamic Navigation in Prosthetic Implant Treatment in Terms of the Clinical Evaluation and Salivary Pro-Inflammatory Biomarkers: A Clinical Study

Contact Info

Product

Resources

About